Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$603 Mln
Revenue (TTM)
$23 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.6
Industry P/E
--
EV/EBITDA
5.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
298,484,992
CFO
$507.02 Mln
EBITDA
$255.31 Mln
Net Profit
$126.72 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
| -28.7 | -13.6 | -39.8 | -42.6 | -36.9 | -- | -- |
|
BSE Sensex*
| 4.3 | 3.9 | 7.7 | 10.3 | 14.5 | 21.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
| -43.6 | -29.2 | -64.5 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
2.1 | 602.9 | 23.1 | -167.9 | -1,329.6 | -16 | -- | 0.6 |
| 8.3 | 1,090.3 | 247.3 | 39.9 | 7.2 | 10.8 | 29.9 | 3.1 | |
| 4.1 | 183.1 | 0.0 | -27.0 | -- | -65.9 | -- | 5.3 | |
| 2.0 | 14.1 | 0.0 | -5.8 | -- | -66.6 | -- | 11.1 | |
| 1.7 | 75.5 | 0.0 | -28.5 | -- | -23.7 | -- | 0.7 | |
| 8.2 | 211.3 | 30.9 | -14.1 | -32.8 | -- | -- | 57.9 | |
| 1.4 | 65.2 | 0.0 | -31.2 | -- | -- | -- | 5.0 | |
| 31.4 | 2,374.9 | 7.5 | -251.5 | -2,936.8 | -33.5 | -- | 3.3 | |
| 0.1 | 95.4 | 27.3 | -47.0 | -174.2 | -21.6 | -- | 0.3 |
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to... treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada. Address: 150 West 4th Ave, Vancouver, BC, Canada, V5Y 1G6 Read more
CEO, President & Chairperson
Dr. Carl L.G. Hansen Ph.D.
CEO, President & Chairperson
Dr. Carl L.G. Hansen Ph.D.
Headquarters
Vancouver, BC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Abcellera Biologics Inc (ABCL) stood at $ 655 Mln as on 31-Mar-25
The share price of Abcellera Biologics Inc (ABCL) is $2.09 (NASDAQ) as of 20-May-2025 16:00 EDT. Abcellera Biologics Inc (ABCL) has given a return of -36.85% in the last 3 years.
Abcellera Biologics Inc (ABCL) has a market capitalisation of $ 603 Mln as on 20-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Abcellera Biologics Inc (ABCL) is 0.59 times as on 20-May-2025, a 81% discount to its peers’ median range of 3.16 times.
Since, TTM earnings of Abcellera Biologics Inc (ABCL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Abcellera Biologics Inc (ABCL) and enter the required number of quantities and click on buy to purchase the shares of Abcellera Biologics Inc (ABCL).
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada. Address: 150 West 4th Ave, Vancouver, BC, Canada, V5Y 1G6
The CEO & director of Dr. Carl L.G. Hansen Ph.D.. is Abcellera Biologics Inc (ABCL), and CFO & Sr. VP is Dr. Carl L.G. Hansen Ph.D..
There is no promoter pledging in Abcellera Biologics Inc (ABCL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
328
|
|
|
145
|
|
|
23
|
|
|
17
|
|
|
15
|
|
|
10
|
|
|
7
|
|
|
1
|
|
|
328
|
| Abcellera Biologics Inc (ABCL) | Ratios |
|---|---|
|
Return on equity(%)
|
-15.98
|
|
Operating margin(%)
|
-1329.6
|
|
Net Margin(%)
|
-726.23
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Abcellera Biologics Inc (ABCL) was $0 Mln.
$0.07
(
